SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “abiraterone-like” agent in comparison with placebo — though radiographic progression-free survival was improved. …
NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weill Cornell Medical College in New York announced …
The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting in New Orleans. Dr. Raymond S Wong MD, PhD — who is a hematology …
NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblastic leukemia and otherwise had very short life expectancies. Stephan A Grupp, …
LONDON—Inequalities in cancer care delivery and overall spending have had a big impact on cancer survival rates in Europe, according to Michel Coleman, Professor of Epidemiology and Vital Statistics at the London School of Hygiene and Tropical Medicine. …
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago
In this edition:
1. Zoledronic …
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin
In this edition Peter Goodwin and Sara Freeman report from:
European Breast Cancer Conference, Berlin, April 15-19, 2008;
Chemotherapy …
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam
In this edition:
1. Lapatinib: Targets Breast Cancer Stem Cells?
Angel Rodriguez, Baylor College, Houston…
Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna
In this edition:
Bevacizumab and Survival in Metastatic Breast Cancer
Source: N Engl J Med 357:26
George Canellos, Dana-Farber Cancer Institute, Boston
Progresson-free survival, but not overall survival, was …
In this edition of Audio News, presented by Peter Goodwin, Giovanni Apolone (Mario Negri Institute, Milan) and Stuart Pocock (London School of Hygiene and Tropical Medicine), talk about:
Risks From Stopping Cancer Trials Early!
– A report from
